The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Background:
Opioids are medicines that control pain. But they are often misused, which can lead to
illness and death. Opioids increase dopamine to the brain, which makes people feel good and
often causes them to crave drugs, leading to misuse and addiction. An investigational drug
ANS-6637 may lower the dopamine surge and stop opioid craving. Midazolam is a drug approved
for anxiety. Researchers want to give the two drugs together and see if ANS-6637 affects
midazolam levels, to help understand how ANS-6637 is used in the body.
Objective:
To study the safety, tolerability, and effects of ANS-6637 taken with and without midazolam.
Eligibility:
Healthy adults 18 65 years old
Design:
Participants will be screened with a medical history, physical exam, and blood and heart
tests. Participants who can get pregnant will have a pregnancy test.
Participants must agree to use 2 types of birth control during the study, if applicable.
Participants will stay at the clinic for 10 days. Meals will be provided. Participants will
not be allowed to:
Leave NIH campus
Eat or drink anything with caffeine, alcohol, or certain juices
Use any nicotine or related products (including vaping)
Use any medicines (including herbal)
During the clinic stay, participants will:
Fast overnight several times
Have blood drawn most days. Twice, a small tube will be inserted in an arm vein for frequent
blood samples.
Repeat screening tests and answer questions about their mood several times
Get midazolam syrup in water on 1 day
Take 6 ANS-6637 tablets by mouth on 5 days
Take both study drugs on 1 day
A few days later, participants will have a follow-up visit to repeat screening tests and
answer questions about their mood.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)